Expert Urges Researchers to Challenge Dogma & Forge Novel… : Oncology Times
An abstract is unavailable.
Related Articles
2024 Orphan Drugs: PDUFA Dates and FDA Approvals
Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs. Below is the list of important regulatory…
Tisagenlecleucel Maintains Long-Term Efficacy in R/R Follicular Lymphoma
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
SEER*Explorer Application
SEER*Explorer provides access to SEER cancer statistics and detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number…
JAAOS – Journal of the American Academy of Orthopaedic Surgeons
Explore JAAOS peer-reviewed articles covering the expanse of orthopaedic medicine and representing o
What is associated with painful polyneuropathy? A… : PAIN
e NeuP) or painless (unlikely NeuP) probable or confirmed neuropathy were investigated clinically, with questionnaires and quantitative sensory testing. Multivariate logistic regression including all variables…
BET Inhibitor Shows Encouraging Safety and Tolerability in Myelofibrosis | Blood Cancers Today
The phase 1 study found that INCB057643, as monotherapy or in combination with ruxolitinib, was generally well tolerated in patients with relapsed or refractory MF.
Best Advances of 2024: Artificial Intelligence/Digital Technology : Neurology Today
An abstract is unavailable.
GLP-1 Receptor Agonist Approved for Treating Obstructive Sleep Apnea : Neurology Today
An abstract is unavailable.